Ohad Benjamini

Fixed-Duration versus Continuous Behandeling for Chronic Lymphocytic Leukemia.

Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymp...

Vastgestelde duur ibrutinib-venetoclax versus chlorambucil-obinutuzumab bij onbehandelde CLL: GLOW definitieve OS